Abstracts tagged "hypertension and uric acid"

Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting
Associations between Serum Uric Acid Level and Coronary Artery Disease
Patricia Kachur^1,2, Satish Tadepalli³, Sergey Kachur⁴ and Pramil Cheriyath³, ¹Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, ²Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ³Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, ⁴Ocala Regional Medical Center, Ocala, FL
Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…
Abstract Number: 2067 • 2017 ACR/ARHP Annual Meeting
Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
Hyon K. Choi¹, Richard Johnson², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Medicine, University of Colorado Denver, Aurora, CO, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: There are significant correlations between serum uric acid (sUA) and blood pressure (BP) in individuals with and without gout.1 Limited data suggest that lowering…
Abstract Number: 102 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study
Lieke E.J.M. Scheepers¹, Jan A. Staessen^2,3, Lutgarde Thijs², Erika Salvi⁴, Annelies Boonen⁵ and Ilja C.W. Arts⁶, ¹Department of Internal Medicine, Division of Rheumatology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands, ²Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology KU Leuven, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium, ³R & D Group VitaK, Maastricht University, Maastricht, Netherlands, ⁴Department of Health Sciences, University of Milan, Milan, Italy, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Department of Epidemiology, CAPHRI School for Public Health and Primary Care, CARIM School for Cardiovascular Diseases, and MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands
Background/Purpose: Uric acid (UA) has been associated with blood pressure (BP) and hypertension. During the final stage of purine metabolism, xanthine oxidoreductase (XOR) breaks down…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].